CN116472292A - 经修饰的蛋白质和蛋白质降解剂 - Google Patents

经修饰的蛋白质和蛋白质降解剂 Download PDF

Info

Publication number
CN116472292A
CN116472292A CN202180058377.0A CN202180058377A CN116472292A CN 116472292 A CN116472292 A CN 116472292A CN 202180058377 A CN202180058377 A CN 202180058377A CN 116472292 A CN116472292 A CN 116472292A
Authority
CN
China
Prior art keywords
ddb1
protein
optionally substituted
alkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180058377.0A
Other languages
English (en)
Chinese (zh)
Inventor
刘京
迈克尔·布鲁诺·普勒韦
马修·伦道夫·李
韩笑然
陈立群
张成伟
王佳亮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Ruiyue Biotechnology Co ltd
Original Assignee
Shanghai Ruiyue Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Ruiyue Biotechnology Co ltd filed Critical Shanghai Ruiyue Biotechnology Co ltd
Publication of CN116472292A publication Critical patent/CN116472292A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
CN202180058377.0A 2020-05-28 2021-05-28 经修饰的蛋白质和蛋白质降解剂 Pending CN116472292A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020092941 2020-05-28
CNPCT/CN2020/092941 2020-05-28
CNPCT/CN2021/081554 2021-03-18
CN2021081554 2021-03-18
PCT/CN2021/096782 WO2021239117A1 (en) 2020-05-28 2021-05-28 Modified proteins and protein degraders

Publications (1)

Publication Number Publication Date
CN116472292A true CN116472292A (zh) 2023-07-21

Family

ID=78722770

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180058377.0A Pending CN116472292A (zh) 2020-05-28 2021-05-28 经修饰的蛋白质和蛋白质降解剂

Country Status (5)

Country Link
US (2) US20230057177A1 (enExample)
EP (1) EP4157888A4 (enExample)
JP (1) JP7898388B2 (enExample)
CN (1) CN116472292A (enExample)
WO (1) WO2021239117A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
WO2022218239A1 (zh) * 2021-04-12 2022-10-20 杜心赟 新型噻唑类化合物及其制备方法和用途
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
AU2022362494A1 (en) * 2021-10-14 2024-05-23 Cullgen (Shanghai), Inc. Modified proteins and protein degraders
US20260209211A1 (en) * 2022-12-16 2026-07-23 Adlai Nortye Biopharma Co., Ltd. Cyclin k degrader and use thereof
CN121358732A (zh) * 2023-03-07 2026-01-16 睿跃生物科技有限公司 治疗癌症的化合物和方法
WO2025054361A1 (en) * 2023-09-05 2025-03-13 Apellis Pharmaceuticals, Inc. Complement inhibition
WO2026128761A1 (en) 2024-12-11 2026-06-18 Nexo Therapeutics, Inc. Covalent p300 inhibitor compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180224435A1 (en) * 2017-02-03 2018-08-09 Celgene Corporation Methods for measuring small molecule affinity to cereblon
US20180327462A1 (en) * 2015-11-07 2018-11-15 Board Of Regents, The University Of Texas System Targeting proteins for degradation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520583D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CA3073125A1 (en) * 2017-08-18 2019-02-21 Cambridge Enterprise Limited Modular binding proteins
EP3864030A4 (en) * 2018-10-12 2022-09-21 The Scripps Research Institute Compounds and methods for dcaf-mediated protein degradation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180327462A1 (en) * 2015-11-07 2018-11-15 Board Of Regents, The University Of Texas System Targeting proteins for degradation
US20180224435A1 (en) * 2017-02-03 2018-08-09 Celgene Corporation Methods for measuring small molecule affinity to cereblon

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MATYSKIELA MARY E等: "A Cereblon Modulator （CC-220）with Improved Degradation of Ikaros and Aiolos", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 61, no. 2, 25 January 2018 (2018-01-25), pages 535 - 542 *

Also Published As

Publication number Publication date
JP7898388B2 (ja) 2026-07-31
EP4157888A4 (en) 2024-07-10
JP2023529099A (ja) 2023-07-07
US20230057177A1 (en) 2023-02-23
EP4157888A1 (en) 2023-04-05
WO2021239117A1 (en) 2021-12-02
US20240066136A1 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
US20240066136A1 (en) Modified proteins and protein degraders
TWI851563B (zh) 作為免疫調節劑之雜環化合物
ES2406730T3 (es) Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi
JP5114610B1 (ja) Ｎ１−ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害薬
ES2429818T3 (es) Espiroamidas sustituidas como moduladores de B1R
CA2944971C (en) 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yl amides
CN103930422A (zh) 杂环化合物及其用途
CN103313968A (zh) Nampt和rock抑制剂
KR20210091832A (ko) Mk2 억제제 및 이의 용도
KR20050122220A (ko) 디펩티딜 펩티다제 억제제
CA3172626A1 (en) Substituted oxoisoindoline compounds for the treatment of cancer
SK4322003A3 (en) Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
CA3094988A1 (en) Thienopyrimidinone compounds
AU2004222341A1 (en) Tetrahydropyranyl cyclopentyl heterocylic amide modulators of chemokine receptor activity
US20250346574A1 (en) Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
JP2013510191A (ja) Ｎ−２ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害薬
TW202302598A (zh) 噻吩并吡咯化合物
US20250235543A1 (en) Modified proteins and protein degraders
TW202342013A (zh) 雜環化合物、其組成物及用其進行治療之方法
KR20140051942A (ko) 아미노메틸 퀴놀론 화합물
CN104837837A (zh) 作为布鲁顿氏酪氨酸激酶抑制剂的噻唑衍生物
EP2981264B1 (en) Inhibitors of bruton's tyrosine kinase
TW202500189A (zh) 雙官能降解劑及其用途
JP2019533639A (ja) Ｃｘｃｒ３受容体アゴニスト
CN121002031A (zh) 作为毒蕈碱型乙酰胆碱受体m4的正向别构调节剂的吡咯并吡啶衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination